01 · THE CUSTOMER PROBLEM
Formulators need excipients that add structure, adhesion, protection or release control while meeting route-specific purity and compatibility requirements.
Mykito provides a controlled fungal chitosan platform that can be engineered as a binder, film former, matrix, carrier or candidate adjuvant-system component.
Modern drug products need excipients that do more than add bulk. Engineered chitosan can bring structure, adhesion, protection and release control into one formulation platform.
02 · RECOMMENDED STARTING POINT
Start with the material designed for the decision.
Chitosan's positive charge, reactive functional groups and tunable polymer structure create a versatile starting point for pharmaceutical formulation. Mykito controls the source, purity, molecular weight and degree of deacetylation so each program can evaluate a material designed around its route, active and performance target.
Without the shell
Controlled fungal sourcing supports a traceable, non-animal supply strategy.
Specification engineered
MW, DDA, purity, charge density and format are selected around the target result.
Application ready
Powder is only the starting point; Mykito also develops films, fibers, gels, coatings and formulations.
One technical partner
Material selection, formulation support and the validation plan are connected from the first sample.
03 · PERFORMANCE TARGETS
Build toward outcomes a buyer can measure.
More than a passive excipient
Chitosan can be investigated as a binder, film former, matrix, carrier or mucoadhesive material—allowing one polymer platform to contribute several formulation functions.
Positive charge creates options
Its cationic character supports interaction with negatively charged mucosal surfaces, biological molecules and formulation components, creating opportunities for adhesion, complexation and delivery-system design.
Protect, organize and release
Films, gels, matrices and particles can be developed to organize or protect an active ingredient, while polymer specification, crosslinking and architecture provide levers for release-profile development.
Versatile across dosage forms
The same material family can be formulated as a powder, coating, film, hydrogel, micro- or nanoparticle, or mucosal delivery system, subject to route-specific compatibility and performance testing.
A controlled fungal source
Mykito's ChitoGene platform avoids crustacean shells and is designed around high purity, low endotoxin, traceability and repeatable specifications for demanding development programs.
Candidate adjuvant systems
Particulate and mucosal chitosan systems can be evaluated for antigen association, co-delivery and immune-response support. Suitability must be established for the specific formulation, route and product.
04 · GO / NO-GO CRITERIA
Define the evidence before testing begins.
The first program is designed around three decision-making outputs—not an open-ended material trial.
Residual, bioburden and endotoxin control
Active and excipient compatibility
Stability, manufacturability and route-specific performance
05 · FROM SAMPLE TO DECISION
A practical application program,
not a bag of powder.
Define
Agree on the function, baseline, constraints and measurable success criteria.
Screen
Select the MW, DDA, purity, dose and physical format that fit the application.
Validate
Test the winning system in the finished formulation, device, process or use environment.
Recommended first request: A route-specific EndoFree ChitoGene grade and excipient-screening brief.
Start the Sample Brief06 · WHY CHITOSAN
Cationic complexation + matrix control
Protonated amino groups can interact with selected anionic actives, polymers and biological surfaces. MW, DDA, crosslinking and architecture then provide levers for adhesion, protection and release.
There is no universal concentration. Grade and dose are screened against pH, interacting ingredients, process conditions and the target performance profile.
Route-specific purity, residuals, compatibility, stability and regulatory suitability are established for the finished system.